Background-Abnormalities in cardiac structure and function in heart failure with preserved ejection fraction may help identify patients at particularly high risk for cardiovascular morbidity and mortality. Methods and Results-Cardiac structure and function were assessed by echocardiography in a blinded core laboratory at baseline in 935 patients with heart failure with preserved ejection fraction (left ventricular ejection fraction ≥45%) enrolled in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial and related to the primary composite outcome of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest, and its components. At a median follow-up of 2.9 years, 244 patients experienced the primary outcome. Left ventricular hypertrophy (adjusted hazard ratio, 1.52; 95% confidence interval, 1.16-2.00), elevated left ventricular filling pressure (E/E′; adjusted hazard ratio 1.05 per 1 integer increase; 95% confidence interval, 1.02-1.07), and higher pulmonary artery pressure assessed by the tricuspid regurgitation velocity (hazard ratio, 1.23 per 0.5 m/s increase; 95% confidence interval, 1.02-1.49) were associated with the composite outcome and heart failure hospitalization alone after adjusting for clinical and laboratory variables. The risk of adverse outcome associated with left ventricular hypertrophy was additive to the risk associated with elevated E/E′. Conclusions-Among heart failure with preserved ejection fraction patients enrolled in TOPCAT, left ventricular hypertrophy, higher left ventricular filling pressure, and higher pulmonary artery pressure were predictive of heart failure hospitalization, cardiovascular death, or aborted cardiac arrest independent of clinical and laboratory predictors. These features, both alone and in combination, identify heart failure with preserved ejection fraction patients at particularly high risk for cardiovascular morbidity and mortality. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00094302.
H eart failure with preserved ejection fraction (HFpEF) is common among elderly people, increasing in prevalence, and is associated with substantial morbidity, mortality, and resource utilization. 1, 2 The cardiac phenotype in this syndrome is heterogeneous. 3 Although left ventricular ejection fraction (LVEF) and LV size have been associated with outcome in HF with reduced LVEF, understanding of the prognostic relevance of measures of cardiac structure and function for cardiovascular morbidity and mortality in HFpEF is limited, and the few large studies have reported conflicting results.
The Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial demonstrated that treatment with spironolactone in HFpEF did not reduce the composite end point of cardiovascular death, aborted sudden death, or HF hospitalization, but was associated with a lower incidence of HF hospitalization. 7 Cardiac structure and function was assessed by echocardiography at baseline in a subset of participants, with a smaller portion undergoing additional assessment at 12 to18 months after randomization to either spironolactone or placebo. 8 We have previously reported a high prevalence of LV structural remodeling, left atrial (LA) enlargement, and diastolic function abnormalities in the TOPCAT echocardiographic substudy 8 In this analysis, we determined the prognostic relevance of abnormalities of cardiac structure and function for incident cardiovascular morbidity (HF hospitalization) and mortality in HFpEF. Specifically, we hypothesized that concentric LV hypertrophy, elevated LV filling pressure reflected in LA enlargement and higher E/E′ ratio, and pulmonary hypertension would be associated with an increased risk of HF hospitalization and cardiovascular death in HFpEF.
Methods

Patient Population
As previously described in detail, 9 TOPCAT was a multicenter, international, randomized, double blind placebo-controlled trial testing the efficacy and safety of the aldosterone antagonist spironolactone, to reduce cardiovascular morbidity and mortality in 3445 adults aged ≤50 years with signs and symptoms of HF and an LVEF ≥45% per local site reading. Randomization was stratified by the presence of either 1 of the inclusion criteria of at least 1 hospitalization in the prior 12 months for which HF was a major component of the hospitalization, or if no qualifying hospitalization, a B-type natriuretic peptide in the prior 60 days ≥100 pg/mL or N-terminal pro-BNP ≥360 pg/mL. All patients provided written informed consent, and the study was approved by the local institutional review board. Baseline demographics and clinical characteristics of the trial population have been previously described in detail. 10 The design and baseline findings of the TOPCAT echocardiographic substudy, including intraobserver reproducibility data for quantitative measures, have been previously described in detail. 8 Briefly, for quality control purposes, each enrolling site was required to submit echocardiographic images obtained <6 months before enrollment from at least the first 2 randomized patients for quantification of LVEF by the echocardiographic core laboratory at the Brigham and Women's Hospital. Consent for review of these echocardiograms was obtained in the main study consent form. At 27 sites, patients consenting to participation in the overall TOPCAT trial were separately consented to participate in the echocardiographic substudy. For participating sites, echocardiograms were performed by a study-specific protocol at baseline and between 12 to 18 months after randomization. From a combined total of 1017 baseline studies received from 204 sites, 935 studies were suitable for quantitative analysis and included in this report. Differences between TOPCAT participants included in the echocardiographic study compared with those not included have been previously reported. 
Echocardiographic Methods
Quantitative measures on all study echocardiograms were performed according to the American Society of Echocardiography recommendations by dedicated analysts at the core laboratory, blinded to clinical information and randomized treatment assignment as previously described. 8, 11, 12 Given the different prognostic utility noted for E/E′ compared with E′, diastolic dysfunction grade was derived using both mitral inflow E/A ratio, tissue Doppler E′, and deceleration time as previously described (see the Data Supplement), 8 and using the following modification of the Olmsted criteria 13 : mild diastolic dysfunction, E/A ratio ≤0.75; moderate diastolic dysfunction, E/A ratio of 0.75 to 1.5 and E/E′ ratio (septal) ≥10; and severe diastolic dysfunction, E/A ratio >1.5 and E/E′ ratio (septal ≥10). Of the 935 analyzable studies included, Doppler data were available in 607 (65% 
Outcomes
Clinical outcomes included cardiovascular death, HF hospitalization, and aborted sudden death during the follow-up period. The primary composite end point for the TOPCAT trial and for this analysis was HF hospitalization, aborted sudden death, or cardiovascular death. All events were reported by the primary site investigator and independently adjudicated by the Clinical Endpoints Center. Definitions of these end points have been previously published. 
Statistical Analysis
The study primary outcome was the composite of HF hospitalization, aborted sudden death, or cardiovascular death. Secondary end points assessed included HF hospitalization and cardiovascular death. Continuous variables are presented as means and SDs or median and interquartile range as specified. Two-sided P values <0.05 were considered significant. Demographic, clinical, laboratory, and echocardiographic characteristics were compared between patients who had an event versus those who did not, using t tests for continuous variables and χ 2 tests for categorical variables. The unadjusted association of each measure of cardiac structure and function with the outcome variables of interest was assessed using a time-to-event analysis with univariable Cox proportional hazards models. A multivariable Cox model for the primary outcome was developed for the subset of patients with echocardiographic data. An initial set of 31 candidate variables reflecting demographics, medical history, and laboratory values, but not echocardiographic variables, was tested for association with the primary composite outcome in univariate Cox regression models. Eighteen of these variables demonstrated a P value <0.20 and were included as candidates for the multivariable Cox model. The final model was chosen using a backward selection procedure on the remaining variables, with a threshold P value of 0.05. Age, sex, race, randomization strata, region of enrollment (Americas versus Russia/Georgia), randomized treatment assignment, core laboratory LVEF, and history of atrial fibrillation were forced into the multivariable model. In addition to these 8 terms forced into the model, the final model also adjusted for heart rate, New York Heart Association class, history of stroke, creatinine, and hematocrit. Details of the nonechocardiographic variables used in developing the multivariable model are provided in Table I in the Data Supplement. Each echocardiographic variable, which was significant at the 0.05 level in the univariate Cox model, was then added to the 13-variable model to determine whether it was significantly related to the clinical outcomes after adjusting for the other 13 variables. Nonlinear relationships of echocardiographic measures with outcomes were assessed using both quadratic terms and restricted cubic splines in univariable and multivariable Cox models.
For selected echocardiographic measurements demonstrating a robust association with clinical outcomes in adjusted analysis (LV mass index [LVMi] , E/E′ ratio, tricuspid regurgitation [TR] jet velocity), the flexible continuous relationship with the primary outcome was displayed via a Cox model using restricted cubic splines. The relationship between echocardiographic measures and total HF hospitalizations during the follow-up period was assessed using a negative binomial model for recurrent events. Because of the limited number of patients with complete data for LVMi, E/E′ ratio, and TR jet velocity, incremental value of these echocardiographic measurements when added to the clinical variables was assessed by comparing the c statistic of the final clinical model versus the clinical model plus echocardiographic variables, with both c statistics obtained via leaveone-out cross-validation. All analyses were performed using Stata version 12. Net reclassification improvement and integrated discrimination improvement associated with echocardiographic variables was assessed for the primary composite end point and HF hospitalization at 4 years using time-to-event data. 14 The primary analysis was performed using raw data, even when some patients had missing values. An additional sensitivity analysis was performed using multiple imputation for missing data ( Numbers represent mean±SD for continuous variables and n (%) for categorical variables. Between-group comparisons for continuous variables were performed using t test. BMI indicates body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HF, heart failure; and SBP, systolic blood pressure.
*Fisher exact P value. in the Data Supplement). Given the arbitrary missing value pattern of the TOPCAT echocardiographic data, we used multiple imputation by chained equations, an iterative imputation procedure (STATA mi impute chained). Imputation was performed for each echocardiographic measure with any missing data and was based on linear regression using 30 baseline clinical variables and the 18 echocardiographic measures as predictor variables and was derived for 40 imputations.
Results
Baseline clinical and echocardiographic characteristics of the 935 TOPCAT patients in the pooled echocardiographic analysis have been previously described in detail. 8 During a median follow-up of 2.9 years (25-75th percentile, 1.5-4.5 years), 244 (26%) patients experienced the primary composite end point of HF hospitalization, aborted sudden death, or cardiovascular death. Hundred and thirty-four patients (14%) had a HF hospitalization alone, 72 (8%) experienced cardiovascular death alone, 36 patients (4%) experienced both, and 2 patients experienced aborted cardiac arrest as a first event. Compared with patients not experiencing an event, those experiencing the primary composite outcome tended to be older, more frequently men and nonwhite, and had a higher prevalence of comorbidities including diabetes mellitus and chronic kidney disease (Table 1) . Patients enrolled in the Americas were also more likely to experience the primary outcome.
Cardiac Structure and Function and the Primary Composite Outcome
LV wall thickness, LVMi, and relative wall thickness were significantly greater in the patients who had the primary composite outcome as compared with those who did not (Table 2 ) and were associated with the primary outcome in univariable Cox models (Table 3) . The relationship between both LV wall thickness and LVMi and risk of the primary composite end point was nonlinear, with the relative increase in risk associated with a given increase in each measure greater at lower values ( Figure 1A ; Figure . In multivariable analysis, adjusting for 13 demographic and clinical covariates including randomized treatment assignment and LVEF, higher LV wall thickness, LVMi, LV hypertrophy (LVH), and concentric hypertrophy remained significantly associated with the primary outcome (Table 3) . Concentric remodeling, in the absence of LVH, was not associated with the primary outcome. The presence of LVH was associated with a 52% higher risk in adjusted analysis, and concentric hypertrophy was associated with a 58% higher risk. Similar findings were noted using LV mass indexed to height 2.7 . Neither LV volumes nor LVEF was associated with higher risk for the primary outcome in the univariable Cox model.
Multiple measures of diastolic function were associated with a higher risk for the primary outcome, including the E/A ratio, septal E′, E/E′ ratio, and LA size reflected in both LA volume and LA width ( Multivariable analysis is adjusted for age, sex, race, randomization strata (prior HF hospitalization or biomarker criteria), region of enrollment (Americas vs Russia or Georgia), randomized treatment assignment, core laboratory LVEF, history of atrial fibrillation, heart rate, New York Heart Association class, history of stroke, creatinine, and hematocrit. Refer to text and Figure I in the Data Supplement for more details. EDA indicates end-diastolic area; EDVi, end-diastolic volume index; EF, ejection fraction; ESA, end-systolic area; ESVi, end-systolic volume index; FAC, fractional area change; HF, heart failure; HR, hazard ratio; LAE, left atrial enlargement; LAV, LA volume; LV, left ventricle; LVH, LV hypertrophy; RV, right ventricle; and RWT, relative wall thickness.
*Variable demonstrates a nonlinear association with the primary composite outcome. Hazard ratios (HRs) provided represent linear approximations. Higher pulmonary artery systolic pressure, reflected in a higher TR jet peak velocity, was significantly associated the primary outcome even after multivariable adjustment, with each 0.5 m/s increase in baseline TR velocity associated with a 23% increase in risk in adjusted analysis. Although right ventricular fractional area change was not associated with clinical outcome, larger right ventricular size-reflected in both the right ventricular end-diastolic and end-systolic areas-was associated with higher risk of the primary outcome in univariable analysis. These associations did not remain significant after multivariable adjustment. The presence of valvular disease, defined as moderate or greater mitral or aortic stenosis or regurgitation (present in 12% of subjects) or presence of a mitral or aortic valve prosthesis (3% of subjects), was associated with increased risk for the primary outcome in unadjusted analysis but not after multivariable adjustment. These findings with respect to LVH, E/E′, and TR jet velocity were not substantially altered in a sensitivity analysis using multiple imputation for missing data (Table V in the Data Supplement).
Cardiac Structure and Function and HF Hospitalization
As with the composite end point, greater LV wall thickness and LVMi and elevated LV filling pressure, both instantaneous (E/E′, E/A ratio) and chronic (LA size), were predictive of incident HF hospitalization and the number of recurrent HF hospitalizations in adjusted analysis (Table 4;  Table III in the Data Supplement). Valvular disease was also related to HF hospitalization, with the presence of at least moderate mitral regurgitation associated with a greater number of recurrent hospitalizations and higher peak transaortic velocity predictive of incident HF hospitalization in multivariable analysis.
Cardiac Structure and Function and Cardiovascular Death
Echocardiographic predictors of cardiovascular death included impaired relaxation (septal tissue Doppler imaging E′; adjusted HR, 0.81, 95% CI, 0.68-0.95; P=0.009) and elevated septal E/E′ ratio (adjusted HR, 1.04; 95% CI, 1.00-1.07; P=0.026; Table IV in the Data Supplement).
Relationship Between Hypertrophy, Filling Pressure, Pulmonary Pressure, and Clinical Outcomes
The presence of LVH without evidence of elevated filling pressure measured by the septal E/E′ ratio was uncommon, whereas elevated E/E′ ratio without LVH was noted in approximately one third of patients. LVH and E/E′ ratio demonstrated an additive influence on risk of the primary outcome (Figure 2) , with the event rate among patients with both risk factors nearly twice that of patients with either finding Figure 1 . Restricted cubic spline analysis demonstrating the unadjusted hazard ratio (HR) for primary composite end point of heart failure (HF) hospitalization, aborted cardiac arrest, or cardiovascular death associated with: (A) left ventricular mass index (n=875), (B) septal E/E′ ratio (n=502), and (C) peak tricuspid regurgitation jet velocity (n=450). *P for nonlinearity <0. 05 . Values presented are a linear approximation. See text for further details. Histograms demonstrate the distribution of each measure in the study population. Multivariable analysis is adjusted for age, sex, race, randomization strata (prior HF hospitalization or biomarker criteria), region of enrollment (Americas vs Russia or Georgia), randomized treatment assignment, core laboratory left ventricular ejection fraction, history of atrial fibrillation, heart rate, New York Heart Association class, history of stroke, creatinine, and hematocrit. Multivariable analysis is adjusted for age, sex, race, randomization strata (prior HF hospitalization or biomarker criteria), region of enrollment (Americas vs Russia or Georgia), randomized treatment assignment, core laboratory LVEF, history of atrial fibrillation, heart rate, New York Heart Association class, history of stroke, creatinine, and hematocrit. CI indicates confidence interval; EDA, end-diastolic area; EDVi, end-diastolic volume index; EF, ejection fraction; ESA, end-systolic area; ESVi, end-systolic volume index; FAC, fractional area change; HF, heart failure; HR, hazard ratio; LAE, left atrial enlargement; LAV, LA volume; LV, left ventricle; LVH, LV hypertrophy; RV, right ventricle; and RWT, relative wall thickness.
*Variable demonstrates a nonlinear association with the time to first HF hospitalization. HRs provided represent linear approximations.
among subjects with LVH and normal TR velocity; adjusted HR, 1.85 [1.
16-2.95]; P=0.010).
Complete data for LV mass, E/E′, and TR velocity were available in 303 patients ( Figure 3A) . A greater number of abnormal measures was associated with a higher observed rate of the primary composite end point and of HF hospitalization alone ( Figure 3B ). In multivariable models including all 3 echocardiographic measures, LVMi and E/E′ ratio remained significantly associated with both the primary composite end point and HF hospitalization. Individually, the presence of LV hypertrophy significantly improved model discrimination for the pri- 
Discussion
The current study has 3 major novel findings. First, LV hypertrophy, elevated LV filling pressure, and higher pulmonary artery pressure were predictive of the primary composite end point and incident HF hospitalization beyond clinical and laboratory characteristics, and both LV hypertrophy and elevated LV filling pressure were also predictive of total number of HF hospitalizations in adjusted analyses. Neither LV volumes nor LVEF was predictive of worse outcomes in this population with an LVEF ≥45%, consistent with prior studies and possibly related to the narrow spectrum of mostly normal values represented in this population. 15 Second, LV hypertrophy, elevated filling pressure, and elevated pulmonary artery pressure frequently coexist, and greater number of abnormalities is associated with higher risk for the primary composite end point and incident HF hospitalization. Finally, the presence of LV hypertrophy, elevated LV filling pressure, and higher pulmonary artery pressure significantly improved risk prediction based on the c statistic, net reclassification improvement, and integrated discrimination improvement. The magnitude of increase in c statistic with addition of these echocardiographic measures (0.03 for the primary composite end point; 0.04 for HF hospitalization) is similar to that observed for risk markers such as age, smoking, and systolic blood pressure for incident cardiovascular disease in the Women's Health Study. 16 LV hypertrophy and elevated LV filling pressure were also robustly associated with total number of HF hospitalizations after adjusting for clinical and laboratory characteristics. Recurrent HF hospitalizations occur as frequently in HFpEF patients as in patients with reduced EF HF, account for a substantial resource utilization, and are associated with greater mortality. 17, 18 Although previous studies have explored echocardiographic predictors of HF hospitalization in HFpEF, 4 limited data are available regarding risk factors for recurrent HF hospitalizations in this condition. Our findings suggest that, beyond clinical factors, echocardiography may help identify HFpEF patients at particularly high risk of recurrent HF hospitalizations.
The association of LV wall thickness, mass, and hypertrophy with the primary composite end point and its components is consistent with findings from echocardiographic substudy of the I-PRESERVE trial and the Northwestern HFpEF Registry. 4, 6 Also similar to our findings, concentric remodeling-in the absence of frank hypertrophy-was not significantly associated with worse outcomes in these previous studies. Although LV hypertrophy is an established risk factor for adverse outcomes across the spectrum of cardiovascular disease, including hypertension, [19] [20] [21] the prognostic relevance of alteration in the wall thickness to cavity ratio (concentric remodeling) in the absence of hypertrophy is less clear. [22] [23] [24] [25] Importantly, however, even TOPCAT patients with normal LV geometry or concentric remodeling demonstrated higher rates of HF hospitalization compared with populations with hypertension or diabetes mellitus without HF. 26 Abnormal LV diastolic performance is commonly thought to be the primary pathophysiologic abnormality in HFpEF, 27 and multiple measures of diastolic function were predictive of cardiovascular morbidity and mortality in TOPCAT. Consistent with data from HF with reduced LVEF, 28 measures of elevated instantaneous LV filling pressure-E/A ratio and E/E′ ratio-were most robustly related to outcomes in unadjusted and adjusted analysis. Measures of diastolic function have been variably associated with outcomes in previous studies of HFpEF. 4, 6, 29 Similar to our findings with LA volume as a measure of chronic filling pressure and that of Burke et al, 6 LA area in the I-PRESERVE echocardiographic substudy was associated with all-cause mortality or cardiovascular hospitalization in unadjusted analysis and with HF hospitalization in unadjusted and adjusted analysis. 4 In contrast, measures of increased instantaneous filling pressure were not predictive in adjusted analysis in that study. These discrepant findings may relate to differences in assessment techniques because the I-PRESERVE study assessed E′ at the lateral annulus, which demonstrated more modest association with outcomes compared with the septal annulus in our study (Table 3; Table II in the Data Supplement). In addition, septal relaxation velocity may be influenced by RV function in addition to LV diastolic function. Evidence of elevated filling pressure occurred commonly in the absence of frank LVH, although LVH without elevated E/E′ was uncommon.
Importantly, the risk associated with elevated instantaneous filling pressure was additive to LVH, suggesting independent contributions of LV structural remodeling and hemodynamic status.
Our finding of the association between TR velocity, a measure of pulmonary artery systolic pressure, and HF hospitalization alone or combined with cardiovascular death is consistent with data from Olmsted County establishing pulmonary hypertension as a risk factor for mortality in HFpEF. 30 In that study, elevation in LV filling pressure did not seem to fully account for severity of observed pulmonary hypertension, suggesting a potential contribution of pulmonary arterial hypertension. However, in our study, elevated TR velocity in the absence of elevated E/E′ was uncommon, occurring on only 5% of participants, and was no longer associated with the primary outcome after adjusting for E/E′. Interestingly, among patients with LVH, pulmonary hypertension identified a particularly high-risk subpopulation. These findings suggest that LV impairment may be the primary determinant of elevated pulmonary pressures in HFpEF and that its presence is associated with particularly high risk.
Greater number of abnormalities in LVMi, E/E′ ratio, and TR velocity was associated with higher risk of adverse outcome. Adding information on these 3 echocardiographic measures to 13 clinical variables significantly improved risk prediction for both the composite end point and HF hospitalization at 4 years. These findings suggest that echocardiographic features may provide useful information in assessing patient risk in HFpEF, although the optimal role of echocardiography and its utility relative to other modalities such as biomarkers requires further investigation.
Several limitations of this analysis should be noted. Although centrally analyzed, a portion of the echocardiograms included in this analysis were clinical echocardiograms not obtained by a prespecified protocol and could have been performed ≤6 months before randomization, which may introduce variability into measurements. Although the study protocol precluded intercurrent myocardial infarction, we cannot exclude that cardiac structure and function may have changed for other reasons during this period. In addition, as a portion of studies were clinical echocardiograms, certain views or measures, particularly Doppler measures, were missing in a large proportion of patients. However, a sensitivity analysis using multiple imputation to account for missing data produced similar findings to the primary analysis (Table V in the Data Supplement). A relatively small number of patients had complete data necessary for assessment of incremental value of echocardiographic measures. We performed leaveone-out cross-validation to determine model c statistics to obviate the risk of model overfitting. Finally, clinical trials by necessity impose inclusion and exclusion criteria, and therefore these findings may not be generalizable to community-based cohorts.
Conclusions
Among HFpEF patients enrolled in TOPCAT, greater LV wall thickness and mass, higher instantaneous LV filling pressure, and higher pulmonary pressure were predictive of the composite of incident HF hospitalization, cardiovascular death, or aborted cardiac arrest beyond clinical and laboratory predictors. These features identified HFpEF patients at particularly high risk for cardiovascular morbidity and mortality.
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